Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for period ended September 30, 2026 announced November 2, 2026.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026 announced November 2, 2026
- Detailed financial results and management commentary available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.025B, up 32% YoY, led by Metabolic Conditions revenue up 44% to $744M
- GAAP net loss $123M versus $31M loss, reflecting Amicus-related amortization, interest expense and acquisition charges
- Non-GAAP income $45M, up 105%, but full-year EPS guidance cut to $2.80-$3.10 from $4.90-$5.10
- Full-year revenue guidance reduced to $3.80B-$3.90B, with order timing uncertainty affecting Metabolic Conditions and VOXZOGO
- VOXZOGO HCH decision target May 30, 2027, while achondroplasia full approval decision remains February 28, 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.